Jazz Pharmaceuticals’ (JAZZ) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report released on Thursday,Benzinga reports. The brokerage currently has a $207.00 price objective on the specialty pharmaceutical company’s stock.

Several other research firms also recently commented on JAZZ. TD Cowen dropped their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Wells Fargo & Company cut their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Robert W. Baird upped their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $175.33.

Jazz Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ:JAZZ opened at $126.67 on Thursday. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a market capitalization of $7.66 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a fifty day moving average of $113.65 and a 200-day moving average of $110.73.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. This trade represents a 0.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This trade represents a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,110 shares of company stock valued at $720,160. 4.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Coldstream Capital Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 7.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock worth $259,000 after purchasing an additional 165 shares in the last quarter. MidWestOne Financial Group Inc. lifted its stake in shares of Jazz Pharmaceuticals by 5.4% in the third quarter. MidWestOne Financial Group Inc. now owns 22,063 shares of the specialty pharmaceutical company’s stock valued at $2,458,000 after buying an additional 1,134 shares in the last quarter. Barclays PLC lifted its stake in shares of Jazz Pharmaceuticals by 19.1% in the third quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company’s stock valued at $4,369,000 after buying an additional 6,289 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Jazz Pharmaceuticals during the third quarter valued at about $2,491,000. Finally, XTX Topco Ltd increased its position in shares of Jazz Pharmaceuticals by 57.5% during the third quarter. XTX Topco Ltd now owns 11,631 shares of the specialty pharmaceutical company’s stock worth $1,296,000 after acquiring an additional 4,245 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.